Protecting Women's Health: The Critical Importance of HPV Vaccination in Africa -written by Poonam Chanchlani (BCA, Data Science)

In the global landscape of sexually transmitted infections (STIs), the Human Papilloma Virus (HPV) stands as the most prevalent culprit. Both men and women worldwide face a 50% risk of HPV infection at least once in their lives, with sub-Saharan Africa (SSA) grappling with one of the highest HPV prevalence rates, averaging 24%. This infection, notorious for causing various types of cancers, particularly cervical cancer (CC), is a leading cause of cancer-related fatalities among SSA women. Fortunately, HPV vaccination has shown efficacy in curtailing HPV-induced cancers. However, SSA nations are lagging in achieving the World Health Organization's (WHO) target of fully vaccinating 90% of girls aged 15 by 2030. This systematic review delves into the barriers and facilitators hindering or supporting HPV vaccination in SSA, intending to illuminate strategies for effective implementation at the national level.

 

Understanding the HPV Threat:

HPV infections strike basal keratinocytes of mucosal and cutaneous epithelia, leading to common dermatological issues and various cancers. Globally, it ranks as the most prevalent STI. The human body typically clears the infection within a couple of years; however, it can persist, leading to serious health consequences, including cancer.

 

Diverse HPV Types and Associated Cancers:

HPV manifests in over 200 distinct types, categorized into five major genera. These can be high-risk (carcinogenic) or low-risk (non-carcinogenic). The most prevalent HPV-associated cancer is CC, almost exclusively linked to high-risk HPV types. Other cancers, such as anal, penile, vaginal, vulvar, and oropharyngeal, have also been attributed to HPV infection.

 

Methodology of the Systematic Review :

This systematic review employs the "Integrated methodology," combining quantitative and qualitative findings in adherence to PRISMA standards. A total of 536 records were initially identified, whittled down to 20 after screening and full-text assessment. The quality of these studies varied, with a mean score of 6.75 for quantitative studies and 7.25 for qualitative ones.

 

The review showcases the intricacies surrounding HPV vaccination in SSA. It highlights disparities in methodological quality among the studies and underscores the importance of addressing these barriers to enhance vaccination efforts.

 

In conclusion, HPV vaccination is a vital tool in preventing HPV-induced cancers in SSA. This review offers valuable insights into the challenges and opportunities faced by the region in achieving effective vaccination coverage, paving the way for improved public health outcomes.